Zug, Switzerland (ots/PRNewswire) - In a new publication, the company's flagship compound proves effective in targeting the harmful pathogen while preserving a healthy microbiome Micreos Pharmaceuticals today announces findings from a study proving the effectiveness of XZ.700, a novel antibacterial enzyme, in ...
The Hague, The Netherlands (ots/PRNewswire) - Micreos announced that it has appointed Joost Goderie to the management board as Chief Financial Officer (CFO). Joost will be working closely together with the other members of the management team to help drive Micreos's growth and deliver its targeted antibacterial technology to the world. He will be responsible for ...
The Hague, Netherlands (ots/PRNewswire) - Dutch biotechnology company Micreos has recruited Matt Regan as CEO of its new Pharmaceutical business that will be based in Switzerland. Following rapid growth, Micreos is preparing to spin-out its Pharmaceutical business into a separate company as per January 2022 to directly access the capital markets. This will help to fund pipeline development to progress its highly ...
The Hague, The Netherlands (ots/PRNewswire) - Dutch biotechnology company Micreos announced it has secured another EUR32 million in funding to further develop its endolysin platform technology, based on targeted killing of only unwanted bacteria. This funding round will help Micreos accelerate its clinical ...
THE HAGUE, Netherlands (ots) - Dutch biotechnology company Micreos announced it has secured EUR30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its ...